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Abstract
Identification of sensitive and specific biomarkers with clinical and translational utility will
require smart experimental strategies that would augment expanding the breadth and depth
of molecular measurements within the constraints of currently available technologies. Exo-
somes represent an information rich matrix to discern novel disease mechanisms that are
thought to contribute to pathologies such as dementia and cancer. Although proteomics
and transcriptomic studies have been reported using Exosomes-Like Vesicles (ELVs) from
different sources, exosomal metabolome characterization and its modulation in health and
disease remains to be elucidated. Here we describe methodologies for UPLC-ESI-MS
based small molecule profiling of ELVs from human plasma and cell culture media. In this
study, we present evidence that indeed ELVs carry a rich metabolome that could not only
augment the discovery of low abundance biomarkers but may also help explain the molecu-
lar basis of disease progression. This approach could be easily translated to other studies
seeking to develop predictive biomarkers that can subsequently be used with simplified tar-
geted approaches.
Introduction
Most mammalian cell types secrete three types of extracellular vesicles either constitutively or
in a regulated manner: exosomes, that are 35–150 nm diameter vesicles; ectosomes (also called
microvesicles), from 100 to 1000 nm; and apoptotic bodies, from 500 to 2000 nm. Exosomes
are formed from intraluminal vesicles and are delivered from multivesicular bodies to the out-
side of the cell by fusion with the extracellular membrane (endolysosomal vesicles) [1–3].
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Microvesicles and apoptotic bodies originate by budding and fission of the plasma membrane.
Exosomes are found in different biofluids including plasma, urine, cerebrospinal fluid, and
uterine aspirates and were first described in 1983 by Pan BT et al. and Harding C et al. [4–5].
Exosomes contain proteins, nucleic acids, lipids, RNAs and small RNAs and metabolites and it
is thought that their principal function is to facilitate cell-to-cell communication under normal
and diseased conditions [6, 7]. They are rich in cell surface molecules that facilitate their fusion
with the receptor membrane and release their cargo in the cytoplasm [8] and are constantly
released into circulation or proximal biofluids under normal and diseased conditions, affecting
either proximal or distant cells. Since exosomes can be easily enriched from biofluids and pro-
vide a fingerprint of their cell of origin, there is a growing interest in using exosomes for the
identification of novel and specific biomarkers with potential utility for diagnosis and progno-
sis of different cancer types [9].
Although there is a general consensus in the scientific community about the use of serial
ultracentrifugation as the method of choice to isolate exosomes, there are still limitations to
confirm the intra-luminal origin of the isolated vesicles (i.e. mainly lack of specific biomarkers).
Thus, enriched vesicles having similar morphology and size and unknown biogenesis are
defined as Exosome-Like Vesicles (ELVs).
Groundbreaking research over last decade has delineated biomarkers that can be used for
early detection of cancer, dementia as well as those that can be used for monitoring response to
therapy [10, 11]. However, identification of biomarkers with high sensitivity and specificity for
a given disease type, still remains a major challenge in the field [12]. Biofluid molecular profil-
ing based approaches have intrinsic limitations for detection of low abundant biomarkers
which are obscured by the presence of high abundance molecules in the matrix. Exosomes, on
the other hand, offer promise as an untapped biomarker resource; given that enrichment of the
exosome fraction is likely to alleviate the dynamic range issue that is a common analytical
problem across a broad range of biomarker identification and characterization studies. More-
over, the exosome cargo is protected from nuclease and protease activity by a lipid bilayer,
resulting in increased stability of the sample [13].
Several studies have described biomarkers associated with cancer cell related ELVs [14–
16]. However, most comparative exosomal profiling studies with a case-control study design
have focused on transcriptomic and proteomic techniques. Given that the ELVs membranes
have a rich lipid and metabolite content, characterizing ELVs metabolomes from different
biofluids is likely to provide new information that could be used for identification sensitive
and specific biomarkers that would also serve as a phenotypic readout since metabolites repre-
sent the end point of cellular processes. A recently published proteoglycan study of the serum
exosomal fraction has shown the value of this matrix as novel biomarker source with potential
clinical utility [17].
Metabolomics is an emerging “omics” field that enables the identification and quantitation
of a wide variety of small molecules that are indicative of metabolic, nutritional and physiologi-
cal status of the patient. This analytical tool allows for the analysis of a large number of samples
in a high-throughput manner, and consequently, permits the understanding of current molec-
ular response of a biological system to any perturbation in its microenvironment [18]. Further-
more, combining chromatography coupled to electrospray ionization mass spectrometry and
multivariate statistical analysis enables the detection of differential abundance of metabolites
between two conditions and adds value to clinical and translational studies focusing on cost-
effective, high through put biomarker development. Metabolomic profiling of human biofluids
using the enriched ELVs fraction represents a surrogate for tissue biopsy as a non-invasive tool
for low abundance biomarker discovery and validation studies. However, there are few meta-
bolic characterization studies reported in literature augmenting these investigations.
Metabolomics and Exosome-Like Vesicles
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In this study, we have characterized ELVs metabolomes derived from human plasma samples
which is a widely used matrix for biomarker studies. In addition, we also analyzed the metabo-
lome of ELVs isolated from cell culture media since cell lines are widely used as a model system
in biomedical research. Moreover, we report the differences on the ELVs metabolomics profile
when comparing two conditions: endometrial cancer (EC) patient plasma samples versus control
subjects; TGF-β treated pancreatic cancer human cell lines versus matched controls as two proof
of principle studies. To our knowledge, this is the first report describing the presence and compo-
sition of metabolite cargo of ELVs derived from plasma and cell culture media using a high reso-
lution mass spectrometry approach. This method development effort represents a first yet critical
step for biomarker discovery using exosomal metabolomics with wide applicability. In addition
to performing extensive characterization of metabolomic content of ELVs in plasma, we also
present an approach that can be generically used for biomarker discovery and validation studies.
Materials and Methods
Patients
Participants in the study attended the Department of Gynecologic Oncology at the Hospital Vall
Hebron in Barcelona, Spain. None of the patients included in the study received treatment prior
to the collection of the biofluids. Final diagnosis was performed in the Department of Pathology
at the same hospital. All patients participating in the study signed an informed consent. The Clin-
ical Research ethics Committee at the Hospital Universitari Vall d’Hebron (Barcelona, Spain)
approved the study. Collection of biofluids for the study included 10 mL of blood from post-
menopausal cancer patients, with endometrioid adenocarcinoma, and control subjects. Samples
were drawn from patients under sterile conditions, de-identified for research purposes and were
processed, aliquoted and frozen at -80°C within four hours of collection. A full description of the
clinic pathologic features of the patients included in both studies are detailed in S1 Table.
Plasma collection
Blood samples were collected in 10 mL EDTA-tubes (Cat# 367525. Pulmolab, CA, USA) and
inverted 10 times at room temperature. Protease inhibitors (1:200, Cat# P8340. Sigma Aldrich,
MO, USA.) were added to the sample. The sample was then centrifuged at 1,300 g during 15
min at room temperature. The supernatant was transferred to a clean tube and centrifuged at
3,000 g for 15 min at 4°C. The supernatant (plasma) was aliquoted and frozen at -80°C.
Cell culture
Human pancreatic carcinoma epithelial-like cell line PANC1 (ATCC1 CRL-1469™) was
obtained from the Tissue Culture Shared Resource of Georgetown University (Washington
DC, USA). PANC1 cells were grown in DMEMmedia supplemented with 10% fetal bovine
serum (HyClone, Logan, UT, USA) and penicillin/streptomycin. Reagents were obtained from
HyClone (Logan, UT, USA). Cells were grown in a 5% CO2 incubator at 37°C.
Cells treatment: Cell lines were grown to 60% confluence, serum starved for 24 h and treated
with 10 ng/mL of TGF-β (Cat # P01137, R&D Systems, MN, USA) for 48 h along with matched
controls. Cells then were harvested and collected in 1.5 mL tubes. Samples were centrifuged at
13,000 rpm for 5 min, supernatant was removed, and cells were kept at -80°C.
Real-Time Reverse Transcription PCR
RNA was purified using the detailed protocol of RNeasy Mini Kit (Cat # 74104, Qiagen, CA,
USA) and quantified by NanoDrop (NanoDrop 2000c, Thermo Scientific, NY, USA). Reverse-
Metabolomics and Exosome-Like Vesicles
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Transcription Reaction was performed following the standard protocol of RT2 First Strand Kit
(Cat # 330401, Qiagen, CA, USA). The cDNA obtained was analyzed by Real Time PCR (Cat #
4309155, SYBR Green, Applied Biosystems, CA, USA). Primers used for the Real Time PCR:
GAPDH-F 3acggatttggtcgtattggg5, GAPDH-R 3tgattttggagggatctcgc5,
E-cadherin-F 3tgcccagaaaatgaaaaagg5, E-cadherin-R 3gtgtatgtgg
caatgcgttc5, N-cadherine-F 3ggacagttcctgagggatca5, N-cadherine-R
3ggattgccttccatgtctgt5, Vimentin-F 3ggctcagattcaggaacagc5, Vimen-
tin-R 3gcttcaacggcaaagttctc5.
ELVs isolation
For ELVs isolation from cell culture, 30 mL of media was centrifuged (for three biological repli-
cates), for 5 min at 300 g in order to remove the cell debris followed by another centrifugation at
2500 g for 20 min. ELVs isolation was performed for cell media and plasma using a modification
of the protocol published by Thery et al [19]. Briefly, samples were centrifuged at 16,500 g at
4°C for 20 min to remove cell debris and fine particulates; subsequently the supernatant was
placed in an ultracentrifuge tube (Cat#0314, Thermo Scientific, NY, USA) and centrifuged at
100,000 g at 4°C for 2 h. The pellet obtained was washed carefully with Tris Buffered Saline
(TBS)-Ca2+ and centrifuged again at 100,000 g at 4°C for 1 h. Finally ELVs (pellet) were re-sus-
pended in 60 μL PBS 1X buffer and frozen at -80°C. Although, exosome isolation can be per-
formed using commercially available kits; many of these use Polyethylene Glycol (PEG) which
interferes with downstreammass spectrometry based analysis.
Nanoparticle Tracking Analysis
The size and number of ELVs was determined using a Nanosight LM10 instrument with Nano-
particle Tracking Analysis (NTA, Malvern Instruments, UK). ELVs were diluted with Milli-Q
water (Milli-Q Synthesis, Merck Millipore, Massachusetts, USA) and the analysis was per-
formed following manufacturer’s instructions. The videos were recorded for 1 min. Measure-
ments were repeated at least 3 times per sample. The data were analyzed using the version 2.3
of the NTA-software. The size of the particles was calculated automatically based on the
Brownian motion rate.
Western blot
Protein extraction of total plasma and plasma ELV fraction was performed by adding RIPA
buffer, incubating at 4°C for 1 h followed by sonication. The supernatant containing exosomal
proteins was collected after 15 min of centrifugation at 15,000 rpm. Protein concentration was
determined using the standard protocol for the Bradford colorimetric method. Samples were
loaded onto SDS-PAGE gels and transferred to a PVDF membrane. Membranes were blocked
with 5% non-fat dried milk in TBS-Tween (0.01%) for 45 min and incubated overnight at 4°C
with the primary antibodies, washed with TBS1x, incubated at room temperature with the sec-
ondary antibody and revealed.
Reagents. Primary antibodies: Flotillin-1 (1:250, Cat# 610821, BD Biosciences, San Jose, CA,
USA), TSG101 (1:500, Cat#ab83. Abcam, MA, USA), CD63 (1:1000, Cat#OP171. Calbiochem,
Merck Millipore, Massachusetts, USA), CD9 (1:250, Cat#555370. BD Biosciences, San Jose,
CA, USA), Rab5 (1:2000, Cat#ab13253, Abcam, MA, USA), CD81 (1:1000, Cat#sc-166028.
Santa Cruz, Texas, USA) and Haptoglobin (1:1000, Cat#ab131236, Abcam, MA, USA). Sec-
ondary antibodies: Goat anti-rabbit, Cat# P0448; rabbit anti-mouse, Cat# P0260, both 1:2000.
Dako, CA, USA). RIPA buffer (5nM EDTA, 150mMNaCl, 1% Triton, 20nM Tris pH8 and
Metabolomics and Exosome-Like Vesicles
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1:200 protein inhibitors). Immobilon Western Chemiluminiscent (Cat#WBKLS0100. Merck
Millipore, Massachusetts, USA).
Metabolomic analyses of ELVs and database search
ELVs isolated from plasma and cell culture media were processed for mass spectrometric analy-
sis as described by Sheikh et al with minor modifications to the original protocol [20]. Initially,
samples were thawed on ice and vortexed. For metabolite extraction, 55 μL (v/v) of ELVs con-
taining approximately 1011–12particles/mL were mixed with 95 μL of water. The tubes were
placed on dry ice for 30 sec followed by 90 sec incubation in a 37°C water bath. The samples
were sonicated for 30 sec. A total of 600 μL of chilled methanol containing internal standards
(5 μL of debrisoquine at a concentration of 1mg/mL and 25 μL of 4-nitrobenzoic acid at a con-
centration of 1mg/mL) were added to each sample. The coefficient of variation (% CV) of each
internal standard for each matrix and condition was calculated (S2 Table), which ranged
between 5.5 to 13.83%. Following vortexing, samples were incubated on ice for 15 min and
600 μL of chloroform were added to each tube, followed by centrifugation at 13,000 rpm at 4°C
for 10 min. The supernatant was transferred to a fresh tube and 600 μL of chilled ACN were
added. Samples were incubated at -20°C overnight and centrifuged at 13,000 rpm at 4°C for 10
min. The supernatant was transferred to a fresh tube and dried under vacuum. This sequential
extraction strategy [going from water (aqueous) to methanol (semi-polar) to non-polar solvent
extraction (chloroform)] allows for a broad range extraction of metabolites. Dried samples were
resuspended in 200 μL of 50% water and 50% methanol followed by UPLC-ESI-Q-TOF-MS
analysis. The solvent composition supports the dissolution andMS analysis of a broad class of
compounds. A total of 5 μL of each sample were injected onto a reverse phase Acquity UPLC
CSH C18 1.7 μm, 2.1 x 100 mm column (Waters Corp.). Two different gradients were used
based on the sample matrix (plasma and cell culture media). MS data acquisition was performed
using ESI-QTOFMS within the mass range of 50 to 1200 mass-to-charge ratio (m/z) in positive
and negative electrospray ionization modes on a (Xevo G2 Q-TOF; Waters Corp.). MS data
were pre-processed using the XCMS software [21]. The Madison Metabolomics Consortium
Database (MMCD) [22], the HumanMetabolome Database (HMDB) [23], LIPIDMAPS [24]
and Metlin [25] were used for accurate mass based putative identification of metabolites. We
performed a multivariate data analysis using Metaboanalyst 3.0 web tool [26]. Identities for a
sub-set of metabolites were validated by tandemmass spectrometry.
Reagents for MS analysis: Chloroform, LC/MS-grade acetonitrile (ACN), water and metha-
nol were purchased from Fisher Optima grade, Fisher Scientific (New Jersey, USA). PBS was
purchased from Invitrogen (Carlsbad, CA, USA). High purity formic acid (99%) was purchased
from Thermo-Scientific (Rockford, IL, USA). Ammonium formate, debrisoquine and 4-Nitro-
benzoic acid (4-NBA) were purchased from Sigma- Aldrich (St. Louis, MO, USA).
Results
Characterization of plasma ELVs
Procuring human plasma samples from biorepositories for biomarker discovery efforts is often
constrained by sample volumes and associated costs of the study; hence our initial goal was to
optimize minimum volume of plasma for ELVs isolation suitable for downstream metabolomic
analysis using high resolution mass spectrometry. For this purpose, we isolated ELVs from dif-
ferent volumes of human plasma (500, 1000 and 2000 μL) as described in methods section
[19]. For all samples, we determined size distribution and concentration of the ELVs enriched
fraction by NTA, protein concentration and total protein amount. The average size of plasma
ELVs was approximately 150 nm (Fig 1A). The final concentration of ELVs correlated with the
Metabolomics and Exosome-Like Vesicles
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starting volume, ranging from 1x1012 particles per mL for 500 μL samples to 7.5x1012 particles
per mL for 2000 μL of plasma. These results are consistent with previous studies that have
reported similar size and number of particles per mL of plasma [27, 28]. Equal volumes of pro-
tein extract corresponding to ELVs purified from 2000, 1000 and 500 μL of plasma were sub-
jected to SDS-PAGE. The gel was also loaded with protein extracted directly from total plasma
(Fig 1B) in order to show the enrichment of exosome specific protein markers in the purified
samples. For the total plasma we loaded the same amount of protein that we loaded for the pro-
tein extract corresponding to ELVs purified from the higher volume (2000 μL). The non-
enriched plasma sample does not show the presence of ELVs specific markers while the
enriched fractions exhibit the presence of these markers in a concentration dependent manner
which in turn was dependent on the initial volume of plasma that was used for enrichment of
the ELVs fraction. These include Flotillin 1, TSG101, CD63, CD9, Rab5 and CD81 (Fig 1B).
However, as seen in the figure, the concentration of ELVs in non-purified plasma samples is
too low for detection of these markers by immunoblotting. Uncropped western blots are
shown in S1A and S1B Fig. In order to understand the amount of co-pelleted artifacts at each
step of the isolation method, we performed an immunoblot against haptoglobin (S1C Fig), a
soluble protein found in plasma, with MVs and ELVs isolated from 2000, 1000 and 500 μL of
plasma. As we expected, we detected the presence of haptoglobin in MVs, since they are col-
lected after the first round of centrifugation (16,500 g for 20 min) where we get rid of the large
vesicles and molecules contained in the sample. However, the following steps of ultracentrifu-
gation permitted to rule out most of the contaminants. We could also detect the presence of
haptoglobin in ELVs isolated from large volumes of plasma (2000 μL), but not from 1000 and
500 μL. These results strongly suggest the enrichment of ELVs from plasma that were ready for
metabolomics characterization using high resolution mass spectrometry.
The Total Ion Chromatograms (TICs) observed in the negative ionization mode for the
metabolites extracted from the ELVs of 500, 1000 and 2000 μL of plasma are shown in Fig 2.
The ratio of relative intensity values for some features detected are shown in S3 Table. Although
with 1 or 2 mL of plasma, a small fraction of metabolites showed improved ion intensity, a large
number of detected metabolites did not show any changes in relative ratios or improvement
Fig 1. Nanoparticle Tracking Analysis (NTA). Determination of the concentration and particle size of
human from 500, 1000 and 2000 μL of human plasma (Panel A). Size distribution of the nanovesicles was
around 150 nm.Western blot analysis to confirm the expression of exosome specific markers (Panel
B). Human plasma ELVs enrichment confirmed in exosomes isolated from different volumes of human
plasma (2000, 1000 and 500 μL) and no presence of exosomal specific markers when loading total plasma
(non-enriched). Lane A through C represent ELVs isolated from 2000, 1000 and 500 μL of plasma
respectively; Lane D represents non-enriched total plasma.
doi:10.1371/journal.pone.0151339.g001
Metabolomics and Exosome-Like Vesicles
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signal to noise ratio for individual metabolites suggesting that 500 μL of plasma was optimal for
performing metabolomics profiling studies using matrices of human plasma samples.
Hence further metabolomics characterization was performed with ELVs isolated from
500 μL of plasma samples that were analyzed using quadrupole time of flight mass spectrome-
try using three biological replicates. The total number of features detected in plasma derived
ELVs samples was 840 and 2198 in the negative and positive ionization mode, respectively.
Next, we annotated the features by performing an accurate mass based database search and an
enrichment analysis using Metlin and Human Metabolome Databases (S4A and S5 Tables).
Our results showed that the metabolome of ELVs derived from plasma maintained a high prev-
alence of glycerophospholipids (possibly representing exosomal membrane contents) and shin-
golipids, representing 29% of the total metabolome composition, such as PI (16:0/22:4), PE
(22:2/16:1), GalCer (d18:2/16:0), GPCho (18:0/14:0) or TG (12:0/12:0/20:5). The fatty acid
esters, amides and alcohols (oleamide, malonyl-CoA among others) represented 16% of the
total metabolites detected in this analytical run while the nucleotides, nucleosides and their
derivatives comprised 17% of the metabolome. Peptides, organic acids and derivatives were
less abundant in the total ELVs metabolite content (Fig 3A). Some of the interesting
Fig 2. Total Ion Chromatograms (TIC) of human plasma Exosome-Like Vesicles (EVLs) in the negative electrospray ionizationmode. ELVs were
isolated from different volumes of human plasma (500, 1000 and 2000 μL) and subjected to TOF-MS analysis. The X-axis represents the chromatographic
retention time while the Y-axis represents the relative intensity.
doi:10.1371/journal.pone.0151339.g002
Fig 3. Metabolomic ELVs composition. Characterization of the metabolite content of human plasma
Exosome-Like Vesicles (P ELVs) (Panel A) or PANC 1 cell culture media (CCM ELVs) (Panel B).
doi:10.1371/journal.pone.0151339.g003
Metabolomics and Exosome-Like Vesicles
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metabolites identified in plasma ELVs included coenzyme Q10, ubiquinone 9, palmitoyl glucu-
ronide, PG (16:0/16:0), 25-hydroxy-hexadehydrovitaminD3, 10-formyldihydrofolate, acetyl
glucosamine bisphosphate, malonyl-CoA, cytidine-5'-monophosphate, N-Arachidonoyl-
L-Serine, tyrosyl-AMP, oleamide, deoxyuridine-diphosphate, picolinic acid and deoxyvitamin
D3 and SM (d18:1/16:0) indicating a wide class of metabolites. A subset of these metabolites
was validated using tandem mass spectrometry (Table 1). Some of these metabolites fall below
the detection limits in routine untargeted metabolomics profiling of plasma samples, possibly
because of ion suppression in presence of other high abundant metabolites that get eluted in
the same chromatographic time scale.
Characterization of ELVs from cell culture media
In order to characterize ELVs in an in vitromodel system, we isolated ELVs from cell culture
media as described in the methods section. The ELVs were characterized using NTA, western
blotting and finally subjected to high resolution mass spectrometry based analysis as described
for plasma ELVs.
We analyzed the bio-composition of ELVs that were isolated from cell culture media obtained
by growing PANC1, a human pancreatic cell line as described in the methods section. We used
three biological replicates for these analyses. The ELVs for each sample were isolated from 30
mL of media. Quantitative analysis of the exosomes isolated using NTA revealed an average size
of 95 nm and average concentration of 1.6 x1010 particles per mL consistent with the size of
ELVs previously reported. The Total Ion Chromatogram (TIC) observed in the positive ioniza-
tion mode for PANC1 is shown in Fig 4. Data were pre-processed using XCMS software that
yielded 596 and 2926 features in the negative and positive electrospray modes respectively.
Database search of ELVs metabolome obtained from cell culture media was performed (S4B
and S5 Tables) and dominated by a majority of glycerophospholipids and shingolipids (56%)
Table 1. Validated metabolites.





Matrix Mode Major CID fragments
PG(16:0/16:0) 123064911
(Pubchem SID)










703.574 0.001 9.993 P ELVs Pos. 184.074




Coenzyme Q10 C11378 861.677 0.000 10.301 P ELVs Neg. 724.8752, 588.8987, 520.9148, 452.9229,
384.9373, 316.9473, 248.9610, 180.9727,
112.9871
Malonyl-CoA cq_00054 853.593 0.001 10.026 P ELVs Neg. 808.727
All-trans-
4-oxoretinoic acid





542.301 0.001 4.049 CCM
ELVs
Pos. 427.2240, 358.1841, 255.1232, 249.1212,
155.1072, 123.0446
List of metabolites contained in plasma Exosome-Like Vesicles (P ELVS) and PANC 1 cell culture media Exosome-Like Vesicles (CCM ELVs) confirmed
by MS/MS.
doi:10.1371/journal.pone.0151339.t001
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and a significant representation of fatty acid esters, amides and alcohols (14%) and nucleotides
and derivatives (7%). We also found a representation of sugars, cyclic alcohols, aromatic com-
pounds, steroids and organic acids which are generally suppressed when whole cell extracts are
used for molecular profiling (Fig 3B). In addition we were able to detect Adenine, aminoadipic
acid, enol-Phenylpyruvate, oleamide, 15-HETrE, 3-Dehydrosphinganine, all-trans-4-oxoreti-
noic acid, N,N-dimethylsphingosine, docosanamide, psychosine sulfate, pentaglutamyl folate
and fructose 1,6-bisphosphate. Some of these metabolites were unambiguously identified by
comparing fragmentation patterns of metabolites acquired in the elevated collision energy
mode (MSE) using mass fragment calculator (Table 1). These results emphasize the presence of
a broad class of metabolites with potential to be used as biomarkers.
ELVs metabolome as a biomarker source
Having characterized the metabolome of ELVs isolated from plasma and cell culture media,
our next goal was to test the possibility of using comparative ELV metabolomic/lipidomic pro-
filing to distinguish between two or more groups. We used two proof of principle studies; the
first study was designed to delineate differences in the ELV profiles enriched from PANC1 cells
treated with transforming growth factor beta (TGF-β) to those that were untreated while in the
other we compared the metabolomic profiles of ELVs isolated from plasma of EC patients to
those obtained from healthy volunteers.
Comparative Profiling of TGF-β treated PANC1 cells. It has been demonstrated that
epithelial to mesenchymal transition (EMT) contributes to metastasis and treatment resistance
of pancreatic cancer cells [29]. It is also well known that TGF-β acts as a driver in cancer pro-
gression through induction of EMT [30]. Therefore, we treated PANC1 cells with TGF-β, while
the control cells were treated with DMSO and interrogated the metabolomic alterations in
ELVs isolated from spent media under these two experimental conditions. We used three
Fig 4. Total Ion Chromatograms (TIC) of PANC1 pancreatic cancer cell culture media Exosome-Like Vesicles (ELVs) in the positive electrospray
ionizationmode. ELVs were isolated from pancreatic cell line PANC 1media and subjected to TOF-MS analysis. The X-axis represents the
chromatographic retention time while the Y-axis represents the relative intensity.
doi:10.1371/journal.pone.0151339.g004
Metabolomics and Exosome-Like Vesicles
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biological replicates for each condition (treated and untreated). The cells and media were col-
lected after treatment (see methods). The cells were tested for EMT induction by TGF-β while
the media were used for ELVs enrichment for subsequent metabolomic analyses. As expected,
at RNA level we observed downregulation of the epithelial marker E-cadherin and the overex-
pression of the mesenchymal marker Vimentin in TGF-β treated cells compared to the controls
(Fig 5A). Next we isolated ELVs from cell culture media and using an untargeted metabolomic
approach we were able to elucidate a variation of the ELVs metabolome in response to TBF-β
treatment. The principal component analysis (PCA) obtained shows a clear separation of the
metabolomic composition of the ELVs due to the treatment (Fig 5B). Metabolites showing sig-
nificant differences (fold change (FC) 2 and p-value 0.05) are listed in S6 Table. UDP-D-
glucosamine (m/z: 550,084) and DG (20:2)/18:1/0:0) (m/z: 647,544) were two of the metabo-
lites identified to be significantly up-regulated after TGF-β treatment.
Metabolomics of plasma ELVs reveals differences between controls and EC patients.
We hypothesized that a compendium of molecular profiles (metabolomics) would provide
insight into alterations that underscore the tumor phenotype in EC patients. Therefore, as a
proof of principle, we compared metabolomic profiles of ELVs isolated from plasma of 13 con-
trol subjects (healthy patients) and 19 EC patients that were analyzed by UPLC-ESI-Q--
TOF-MS. Multivariate analysis was performed in order to elucidate the differences in the ELVs
metabolome composition in the two study groups. The differential abundance of metabolites
was visualized as a heat map (Fig 6A) and PCA (Fig 6B) which indicated a differential pattern
of the metabolites found in the ELVs isolated from EC plasma patients compared to the con-
trols. Several significant metabolites did not yield an accurate mass based putative identifica-
tion when searched against several databases which remains a major challenge in the field. The
differentially abundant metabolites with putative IDs included substituted sugars and amino
acids. Further characterization and validation of these findings is ongoing in our laboratory.
Fig 5. Panel A. TGF-beta induces epithelial to mesenchymal transition (EMT) in PANC1 cells. Real Time PCR analysis showed a decrease of the
epithelial marker E-cadherin (p-v<0.05) and an increase of the mesenchymal markers N-Cadherin and Vimentin (p-v<0.05) expression after TGF-β treatment
in PANC1 cells. Panel B. Principal Component Analysis (PCA) of exosomal metabolome for MS negative ionizationmode showing the separation
between the two study groups. TGF-β treated (T) and control (C) PANC1 cells. We analyzed three replicates per condition. The x-axis shows interclass
separation while y-axis illustrates the intra-class variability on Y-axis.
doi:10.1371/journal.pone.0151339.g005
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Discussion
In this study, we present a broadly applicable approach for metabolomic profiling of ELVs iso-
lated from human plasma as well as cell culture media. We chose these two matrices for opti-
mizing metabolomics methodologies since these are widely used in studies with clinical and
basic science focus respectively. Furthermore, the use of ELVs as a biomarker resource is useful
since they can be isolated from most bodily fluids and their rich content is protected from deg-
radation, allowing for circulation as well as for cell-to-cell communication of molecules and
metabolites that would not be stable in free plasma and other biofluids [31]. It has also been
reported that the ELVs secretion rate derived from tumoral cells is much higher than the rate
for healthy cells; being involved in signal transmission in tumoral microenvironment [32].
We started out by confirming isolation and enrichment of ELVs fraction from human
plasma and cell culture media by immunoblotting. Next, we characterized their size and con-
centration by Nanoparticle Tracking Analysis. A set of common and well established ELVs
markers were identified in the extractions enriched in vesicles around 95–150 nm confirming
the specific enrichment of ELVs. We also determined that 500 μL volume of plasma is optimal
for generating high quality MS data for profiling the metabolomic and lipidomic content of the
ELVs; increasing plasma volumes further does not add significant value to the number and sig-
nal to noise ratio of the detected metabolites.
A sub-set of the metabolites identified in plasma ELVs were validated including PG (16:0/
16:0), N-arachidonoyl-L-serine, SM (d18:1/16:0), coenzyme Q10 and malonyl CoA. PG (16:0/
16:0) is a glycerophospholipd precursor of cardiolipin. Cardiolipin is found in the inner mito-
chondrial membrane and a change in its concentration and distribution in this organelle is
known to cause several diseases including cancer and aging [33]. It has also been reported that
Fig 6. Multivariate analysis reveals distinct metabolic changes in plasma derived Exosome-Like Vesicles (ELVs) isolated from endometrial cancer
(EC) patients compared to the control subjects. Panel A. Heat map visualization of ion rankings of volcano plot based m/z, corresponding to their relative
levels (intensity) in plasma ELVs isolated from EC patients and control subjects for MS positive ionization mode. Each row on the heat map represents a
unique feature with a characteristic mass to charge ratio and retention time while each column represents one subject. Panel B. Principal Component
Analysis (PCA) plot for MS positive ionization mode showing the separation between EC and control plasma ELVs. The x-axis shows interclass separation
while y-axis illustrates the intra-class variability.
doi:10.1371/journal.pone.0151339.g006
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the endocannabinoid N-arachidonoyl-L-serine can have a neuroprotective effect in maintain-
ing the undifferentiated state of some cells [34] and can promote cell proliferation, migration
and angiogenensis [35]. Moreover, recent studies have revealed that Coenzyme Q10, apart
from its antioxidant functions, also regulates the expression of genes involved in cell signaling
and transport. The incorporation of Coenzyme Q10 in experimental lipovesicles enhanced
their cell uptake [36] and an increase of Coenzyme Q10 concentration in vesicles prolonged
their circulation in blood [37].
Furthermore, we analyzed the biochemical composition of cell culture media ELVs and we
were able to identify some metabolites such aminoadipic acid that is an intermediate metabo-
lite in the lysine pathway. It acts also as an antagonist of the neuroexcitatory activity and inhib-
its the production of kynurenic acid in some tissues [38]. Enol-phenylpyruvate was also
present in cell culture ELVs and is related to phenylalanine and tyrosine metabolism pathways
as well as to macrophage induced inflammatory processes [39]. We found also 15-HETrE,
which is a polyunsaturated fatty acid involved in tumorigenesis and in the modulation of ara-
chidonic acid metabolism. It also regulates the activity of cyclooxygenase-2 by inhibiting its
expression [40]. Finally, all-trans-4-oxoretinoic acid was also present in the ELVs. It is an iso-
mer of retinoic acid that is actively involved in cell-to-cell communication by modulating gap
junctional activity [41]. There was an overlap in the different classes of metabolites obtained
from plasma and cell culture media ELVs although the distribution across different classes was
matrix dependent (Fig 3).
As expected, the major class of metabolites were glycerophospholipids, which are integral
components of the exosomal membranes and could majorly contribute to high phospholipid
content associated with human plasma samples. Interestingly, we also found metabolites that
belong to different classes including organic acids (several glycolytic intermediates), cyclic alco-
hols, steroids, prenols and amino acid conjugates as well as sugar and sugar conjugates (S4A
and S4B Table) both in plasma and cell culture media ELVs. In our experience with routine
plasma profiling experiments many of these metabolites fall below the instrumental limit of
detection. Hence we compared the number of features obtained from regular plasma profiling
with those obtained from ELVs fraction enriched from 500 μl of plasma (Fig 7). There was little
overlap of detected metabolites between the two matrices most probably because of sensitivity
range of the instrument for detecting metabolites from 25 μl of human plasma that we rou-
tinely use for untargeted metabolomics profiling [42]. This underscores the importance of
enriching this fraction for low abundance biomarker discovery using plasma samples. Thus,
detection of these compounds with significant implications in cell-to-cell communication and
signaling, regulation and metabolic status is of critical importance for novel, low abundance
biomarker discovery. We further propose that these compounds can be further characterized
from whole plasma extracts using multiple reaction monitoring based targeted mass spectrom-
etry thus dramatically increasing the sensitivity and specificity of the assay as well as the flexi-
bility of multiplexing such that multiple metabolites could be assayed in a single injections.
This combinatorial approach (Fig 8) can also be used for testing clinical utility of biomarkers
in clinical samples as well as to compare different conditions when performing in vitro or in
vivo experiments. Furthermore, we present the utility of using MS in order to reveal the differ-
ences in ELV metabolomic profiles of EMT-induced PANC1cell line (as compared to control)
and EC samples (as compared to controls). We further propose that the low abundance bio-
markers discovered using ELVs from bodily fluids could then be analyzed using targeted mass
spectrometry from plasma directly since the sensitivity would be greatly enhanced. The
approach described here can be generically used for biomarker identification of cancer or other
pathologies thus furthering the precision medicine paradigm. Thus findings from our study
have great value given that not only do these present a standardized approach for mass
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spectrometry based metabolomics profiling, but also provide evidence for using ELVs metabo-
lomics (derived from human fluids as well as from cell culture media) as a rich matrix for bio-
marker discovery for studies with basic science, clinical or translational focus.
Conclusions
Biomarker detection and characterization from complex biological matrices, especially for
markers that are low in abundance, remains a challenge. There is increasing evidence that
underscores the importance of ELVs as carriers of important cellular information that can be
Fig 7. Comparison of the number of features detected in total plasma (non-purified) or plasma ELVs.
The number of common and unique features for each type of sample is represented for the negative (Panel
A) and positive (Panel B) electrospray ionization mode.
doi:10.1371/journal.pone.0151339.g007
Fig 8. Workflow. Schematic showing experimental design in order to analyze the composition of exosome-
like vesicles (ELVs) derived from plasma samples and cell culture media. (WB = western blot,
NTA = nanoparticle tracking analysis).
doi:10.1371/journal.pone.0151339.g008
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used for defining specific changes in health and disease. Herein, we present an experimental
pipeline that can be broadly applied for identification of low abundance biomarkers and char-
acterization in clinical samples. Finally, we demonstrate that ELVs represent an untapped
source for metabolic and lipidomic biomarker discovery with high clinical and translational
relevance. We believe that the methodology presented here will provide an impetus to the
growing field of metabolomics underscoring its ability to delineate biomarkers that can be used
for pre-clinical detection as well as for following the natural history of disease progression.
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